Erratum: Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline

The clinical practice guideline on the treatment of tuberculosis, published in the November 15, 2019, issue of the Journal (1), contains several errors. On page e124, the first sentence under the heading Additional Considerations as well as the first full sentence in the middle column should have contained “less than” symbols instead of “greater than” symbols. Here are the corrected sentences:

When applying the eligibility criteria from WHO for using the shorter-course, standardized regimen to the population included in our PS-matched IPDMA (7, 253), <15% of individuals would have been eligible for the standardized, shorter regimen.

In the United States, <15% of patients with MDR-TB would be eligible for the shorter-course MDR-TB regimen (256).

On page e103, the penultimate sentence in the middle column should read:

To reflect meaningful variations in the duration of the intensive regimen after conversion, stratified analyses were conducted: strata were 0 to 1.0 months, 1.01 to 3.0 months, 3.01 to 5.0 months, 5.01 to 7.0 months, and 7.01 [not 7.1] to 15.0 months (see Table 5).

Finally, on page e130, third column, the reference number at the end of the first sentence of the Benefits section should be 333 (not 290). For the convenience of our readers, the Journal is replacing the online version of the article with a corrected version; we apologize for the errors. There are no changes in the executive summary of the guideline.